Prenatal Vaccination With RSV Prefusion F Does Not Increase Risk for Preterm Birth
By Elana Gotkine HealthDay Reporter
FRIDAY, July 12, 2024 -- Prenatal vaccination with a nonadjuvanted bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) protein subunit vaccine is not associated with an increased risk for preterm birth (PTB), according to a study published online July 8 in JAMA Network Open.
In a retrospective observational cohort study, Moeun Son, M.D., from the Weill Cornell Medical College in New York City, and colleagues examined the association between prenatal RSV vaccination status and perinatal outcomes among patients who delivered during the vaccination season. Data were included for 2,973 pregnant individuals, 34.5 percent of whom received prenatal RSVpreF vaccination.
The researchers found that 60 patients who had evidence of prenatal vaccination experienced PTB compared with 131 of those without evidence of prenatal vaccination (5.9 versus 6.7 percent). There was no association seen for prenatal vaccination with an increased risk for PTB after adjustment for potential confounding variables and addressing immortal time bias. Pregnancy and neonatal outcomes did not differ significantly based on vaccination status, but an increased risk for hypertensive disorders of pregnancy was seen in the time-dependent model.
"In the main analyses, there were no significant differences in maternal or perinatal outcomes between patients who had electronic health record evidence of prenatal RSVpreF vaccination and those who did not," the authors write.
Two authors disclosed ties to Pfizer, the manufacturer of the RSVpreF vaccine.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Transcatheter PDA Closure Increasingly Used for Very Low Birth-Weight Infants
MONDAY, July 15, 2024 -- For very low birth-weight (VLBW) infants, transcatheter closure of the patent ductus arteriosus (PDA) is increasingly used, with selected short-term...
First-Trimester COVID-19 Vaccine Does Not Increase Risk for Birth Defects
THURSDAY, July 11, 2024 -- First-trimester mRNA COVID-19 vaccine exposure is not associated with an increased risk for selected major structural birth defects, according to a...
Nirsevimab Effective Against RSV-Linked Bronchiolitis Hospitalization
WEDNESDAY, July 10, 2024 -- Nirsevimab therapy is effective for reducing the risk for hospitalization for respiratory syncytial virus (RSV)-associated bronchiolitis among infants...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.